Esperion (ESPR) announced that HLS Therapeutics (HLTRF) has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks another important milestone in our global strategy to expand access to bempedoic acid products for patients who urgently need better options to manage their LDL-C and reduce cardiovascular risk. We remain deeply committed to delivering innovative therapies that address unmet medical needs and improve outcomes for patients around the world,” said Sheldon Koenig, President and CEO of Esperion.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy
- Esperion announces new data from CLEAR outcomes on NEXLETOL
- Promising Clinical Data and Strong Market Presence Drive Buy Rating for Esperion
- Esperion Therapeutics Reports Strong Q3 Revenue Growth
- Esperion Therapeutics Reports Strong Q3 Growth Amid Challenges